

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGIES PROGRAMME

Equality impact assessment – Scoping

HST Inotersen for treating hereditary transthyretin-related amyloidosis

Batch 58

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the scoping process it was highlighted that one particular mutation, V122I, predominantly affects older people with African-Caribbean family origins.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will make recommendations which apply equally regardless of age or ethnicity, so a difference in disease prevalence in different age and ethnic groups does not in itself represent an equality issue. If appropriate, the committee will consider whether its recommendations could have a differential impact on older people with African-Caribbean family origins.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name):Sheela Upadhyaya

Date: 29/05/2018